November 5, 2025 — Crescita Therapeutics Inc. Reports Q3-2025 Financial Results —
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) reported its financial results for the third quarter ended September 30, 2025. Revenue increased to $5,393, gross profit was $2,855, operating expenses decreased to $3,017, and net income was $753. Ending cash was $8,308, an increase of $124 for the quarter.
In August, Crescita acquired select assets of Laboratoire Provence-Canada Inc. for $775, including the Bacti Control® brand. The company also secured an exclusive five-year supply agreement with a former LPC customer.
In May, Crescita terminated its licensing agreement with Croma Pharma GmbH for Pliaglis®, regaining all development and commercialization rights and receiving a €575,000 (CA$902,000) termination payment. The company is exploring potential new partnerships to commercialize Pliaglis in these markets.
Serge Verreault, President and Chief Executive Officer of Crescita, noted the company’s third quarter results reflected growth in the Manufacturing segment, driven by the timing and the fulfillment of significant volumes for new and existing clients.
Source: Crescita Therapeutics Inc.
